An automated blood sampler for simultaneous sampling of systemic blood and brain microdialysates for drug absorption, distribution, metabolism, and elimination studies

Journal of Pharmacological and Toxicological Methods

Volumn 49, Issue 1, 2004, Pages 57-64

  Gunaratna, P Chandrani ^a   Kissinger, Peter T ^a   Kissinger, Candice B ^a   Gitzen, James F ^a  

^a BIOANALYTICAL SYSTEMS INC   (United States)

Author keywords

Automated blood sampler; Microdialysis; Neurotransmitters; Olanzapine; Pharmacodynamics; Pharmacokinetics

Indexed keywords

OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; AUTOMATION; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CORPUS STRIATUM; DIALYSATE; DIALYSATE LEVEL; DOPAMINE BRAIN LEVEL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; MALE; NONHUMAN; PLASMA CLEARANCE; RAT; SYSTEMIC CIRCULATION;

ANIMALIA;

EID: 0345599286     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8719(03)00058-3     Document Type: Article

References (19)

1. Aravagiri M., Teper Y., Marde S.R. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharmaceutics & Drug Disposition. 20:1999;369-377.
2. Bohs C., Cregor M., Gunaratna G., Kissinger C. Culex automated blood sampler: Part II. Managing freely-moving animals and monitoring their activity. Current Separations. 18:2000;147-151.
3. Bymaster F.P., Hemrick-Luecke S.K., Perry K.W., Fuller R.W. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 124:1996;87-94.
4. De Lange E.C., Danhof M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: Implications of the barriers between blood and brain. Clinical Pharmacokinetics. 41:2002;691-703.
5. Deguchi Y., Morimoto K. Application of an in vivo brain microdialysis technique to studies of drug transport across the blood-brain barrier. Current Drug Metabolism. 2:2001;411-423.
6. Gunaratna C., Cregor M., Kissinger C. Pharmacokinetic and pharmacodynamic studies in rats using a new method of automated blood sampling. Current Separations. 18:2000;153-157.
7. He H., Kramp R., Ramos L., Bakhtiar R. A preliminary study on the feasibility of an automated blood-sampling system in conjunction with liquid chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry. 15:2001;1768-1772.
8. Jamali F., Kunz-Dober C.M. Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery. British Journal of Clinical Pharmacology. 47:1999;391-396.
9. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. American Journal of Psychiatry. 155:1998;921-928.
10. Kassahun K., Mattiuz E., Nyhart E. Jr., Obermeyer B., Gillespie T., Murphy A., Goodwin R.M., Tupper D., Callaghan J.T., Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metabolism and Disposition. 25:1997;81-93.
11. Lee C., Sarna S.K. Central regulation of gastric emptying of solid nutrient meals by corticotropin releasing factor. Neurogastroenterology and Motility. 9:1997;221-229.
12. Mattiuz E., Franklin R., Gillespie T., Murphy A., Bernstein J., Chiu A., Hotten T., Kassahun K. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metabolism and Disposition. 25:1997;573-583.
13. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:1999;106S-115S.
14. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
15. Peters S., Hampsch J., Cregor M., Starrett C., Gunaratna G., Kissinger C. Culex ABS: Part I. Introduction to automated blood sampling. Current Separations. 18:2000;139-145.
16. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Science. 68:2000;29-39.
17. Scheepers F.E., Gispen-de Wied C.C., Westenberg H.G., Kahn R.S. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology. 25:2001;468-475.
18. Seeman P. Atypical antipsychotics: Mechanism of action. Canadian Journal of Psychiatry. 47:2002;27-38.
19. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology. 25:2001;633-641.